| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5652233 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(11 years ago) | |
| US7342005 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(11 years ago) | |
|
US5652233 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(10 years ago) | |
|
US7342005 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(10 years ago) | |
| US5478820 | MSD SUB MERCK | Antibiotic compounds |
Nov, 2015
(8 years ago) | |
|
US5478820 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
May, 2016
(7 years ago) | |
| US5952323 | MSD SUB MERCK | Carbapenem antibiotic |
May, 2017
(6 years ago) | |
|
US5952323 (Pediatric) | MSD SUB MERCK | Carbapenem antibiotic |
Nov, 2017
(6 years ago) | |
Invanz is owned by Msd Sub Merck.
Invanz contains Ertapenem Sodium.
Invanz has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Invanz are:
- US5652233
- US7342005
- US5652233*PED
- US7342005*PED
- US5478820
- US5478820*PED
- US5952323
- US5952323*PED
Invanz was authorised for market use on 21 November, 2001.
Invanz is available in injectable;intramuscular, intravenous dosage forms.
Invanz can be used as treatment of bacterial infectious disease.
The generics of Invanz are possible to be released after 15 November, 2017.
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Treatment: Treatment of bacterial infectious disease
Dosage: INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
INVANZ family patents
